Last reviewed · How we verify
NCT04881331: SurgiNose
Intraoperative Tissue Identification by Analyzing Surgical Smoke
trial testing Analysis of electrosurgical smoke. in Breast Cancer in 20 participants. Completed in 26 December 2019.
26 December 2019
Quick facts
| Lead sponsor | Tampere University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 9 October 2019 |
| Primary completion | 26 December 2019 |
| Estimated completion | 26 December 2019 |
| Sites | 1 location across Finland |
Drugs / interventions tested
- Analysis of electrosurgical smoke.
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Tampere University Hospital
Who can join
18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SurgiNose is a single-center, non-randomized feasibility study aiming to evaluate the feasibility of intraoperative tissue analysis using differential mobility of surgical smoke generated with electrocautery. Patients receive standard-of-care breast conserving surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04881331
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Tampere University Hospital trials
Trials by the same sponsor.
- NCT07315568 — Couples and Microbial Diversity · not yet recruiting
- NCT07128992 — Need-driven Treatment of the Patients With Type 1 Diabetes · not yet recruiting
- NCT07042139 — No Reduction Compared to Closed Reduction for Distal Radius Fractures in Patients Over 65 or Older · NA · recruiting
- NCT07528833 — Health Effects of Mindfulness Based Stress Reduction Course in Treatment of Back Pain · NA · recruiting
- NCT06711796 — Measurement of Muscle Relaxation of the Hand in From Two Muscles and Two Hand Positions · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04881331 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tampere University Hospital
- Last refreshed: 11 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04881331.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing